News | March 06, 2021
Sun Pharma arm to acquire stake in WRS Bioproducts, Australia
The consideration to be paid will be AUD 2.0 mn for 12.5% stake.
The consideration to be paid will be AUD 2.0 mn for 12.5% stake.
The next phase of growth in pharma depends on the industry-oriented workforce, risk investment, academic revamp, and creation of R&D hubs, say experts .
The Indian pharma industry has grown at a compounded growth rate of ~11% in the domestic market and ~16% in exports over the last two decades
Pharma industry is ready to embrace technology platforms with a keen focus on automation in manufacturing and digital health investment.
Merck forecasts organic growth of EBITDA pre in a high single-digit to low teens percentage range in 2021.
A mix of favorable government policies and a positive environment will create a win-win situation for all stakeholders
Reflecting on the learning during the pandemic, industry is aiming to push innovation in R&D and implement automation and digital technologies across various operational levels.
_256_384.jpg)
The company expects to generate an EBITDA margin before special items of around 27 percent in 2021.
Building upon the momentum gained by pharma sector during the pandemic, Indian Pharmaceutical Alliance is leaving no stone unturned to create a faster road to recovery.
The Govt. launched the PLI scheme for bulk drugs with a financial outlay of Rs 6,940 crores across 53 APIs over 6 years.
Subscribe To Our Newsletter & Stay Updated
